Combining Insulin with a GLP-1 Drug Improves Pancreatic Beta-Cell Function in Type 2 Diabetes
The fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improved beta-cell glucose sensitivity by 35% while sparing endogenous insulin release over 26 weeks in people with type 2 diabetes.
Quick Facts
What This Study Found
After 26 weeks, iGlarLixi produced a 35% median increase in beta-cell glucose sensitivity compared to GLP-1RA alone (p=0.0032). HbA1c decreased significantly more with iGlarLixi than with GLP-1RA alone (p<0.0001).
Notably, iGlarLixi reduced both fasting and stimulated insulin secretion (both p<0.0001 vs. GLP-1RA), indicating that the beta cells were being spared from overproduction while functioning more efficiently. The incremental meal tolerance test glucose area also showed a larger reduction with iGlarLixi (p<0.0001). Body weight increased modestly in the iGlarLixi group (+1.7 kg, p<0.0001). In the GLP-1RA-only group, despite weight loss and HbA1c improvement, no beta-cell function parameters changed significantly.
Key Numbers
How They Did This
Post-hoc analysis of the LixiLan-G randomized trial (NCT02787551) including 351 participants with type 2 diabetes on metformin. Participants were randomized to iGlarLixi (n=189) or continued daily/weekly GLP-1RA (n=162) for 26 weeks. Beta-cell function was assessed using 2-hour meal tolerance tests with timed glucose and C-peptide measurements at baseline and week 26, analyzed with mathematical modeling to derive insulin secretion and glucose sensitivity parameters.
Why This Research Matters
Beta-cell dysfunction is the core defect driving type 2 diabetes progression. Finding that iGlarLixi not only improves blood sugar control but actually improves beta-cell function and spares insulin production suggests it may help preserve beta-cell health over time. This is a shift from simply treating high blood sugar to potentially modifying the underlying disease process.
The Bigger Picture
Fixed-ratio combinations of basal insulin and GLP-1 receptor agonists represent a practical advance in diabetes management, simplifying treatment by combining two drugs in one injection. This study adds a mechanistic dimension — showing that the combination doesn't just lower blood sugar but actually improves how beta cells function. This finding supports the growing evidence that GLP-1-based therapies may have disease-modifying potential in type 2 diabetes.
What This Study Doesn't Tell Us
This was a post-hoc analysis of a clinical trial, not designed primarily to assess beta-cell function. The 26-week duration may not capture longer-term effects on beta-cell health. The modest weight gain with iGlarLixi is a trade-off compared to the weight loss seen with GLP-1RA alone. Only participants on metformin were included, limiting generalizability. Mathematical modeling of beta-cell function is an indirect assessment.
Questions This Raises
- ?Does the improvement in beta-cell function with iGlarLixi persist or increase beyond 26 weeks?
- ?Could iGlarLixi slow the progressive beta-cell decline that characterizes type 2 diabetes?
- ?How does iGlarLixi's beta-cell effect compare to newer combinations like insulin plus tirzepatide?
Trust & Context
- Key Stat:
- 35% increase in β-cell glucose sensitivity iGlarLixi improved beta cells' ability to sense and respond to blood sugar by 35% compared to GLP-1RA alone, while simultaneously reducing the overall insulin production burden on the pancreas.
- Evidence Grade:
- This is a post-hoc analysis of a randomized controlled trial with a substantial sample size (351 participants). The RCT design and detailed beta-cell function assessment provide reasonably strong evidence, though the post-hoc nature means the findings should be confirmed in prospective studies.
- Study Age:
- Published in 2022 based on the LixiLan-G trial, this study provides mechanistic insight into a combination therapy that is currently available for clinical use.
- Original Title:
- Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
- Published In:
- Diabetes, obesity & metabolism, 24(6), 1159-1165 (2022)
- Authors:
- Ferrannini, Ele(2), Niemoeller, Elisabeth, Dex, Terry, Servera, Soraly, Mari, Andrea
- Database ID:
- RPEP-06122
Evidence Hierarchy
Frequently Asked Questions
What is iGlarLixi and how does it work?
iGlarLixi is a single-injection combination of insulin glargine (a long-acting basal insulin) and lixisenatide (a GLP-1 receptor agonist). The insulin controls fasting blood sugar levels, while lixisenatide slows stomach emptying and reduces post-meal blood sugar spikes. Together, they also improve how the pancreas's beta cells respond to glucose.
Why is improving beta-cell function important in diabetes?
Type 2 diabetes progressively worsens because beta cells — the pancreatic cells that make insulin — gradually lose their ability to respond to blood sugar. Treatments that improve beta-cell function may not only control blood sugar better but could potentially slow disease progression. This study showed that iGlarLixi improved beta-cell glucose sensitivity by 35% while reducing the demand placed on beta cells.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06122APA
Ferrannini, Ele; Niemoeller, Elisabeth; Dex, Terry; Servera, Soraly; Mari, Andrea. (2022). Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.. Diabetes, obesity & metabolism, 24(6), 1159-1165. https://doi.org/10.1111/dom.14688
MLA
Ferrannini, Ele, et al. "Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.." Diabetes, 2022. https://doi.org/10.1111/dom.14688
RethinkPeptides
RethinkPeptides Research Database. "Fixed-ratio combination of insulin glargine plus lixisenatid..." RPEP-06122. Retrieved from https://rethinkpeptides.com/research/ferrannini-2022-fixedratio-combination-of-insulin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.